Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder

Nagisa Aoyama, Nagahide Takahashi, Kiyoyuki Kitaichi, Ryoko Ishihara, Shinichi Saito, Nobuhisa Maeno, Xiaofei Ji, Kenji Takagi, Yoshimoto Sekine, Masaomi Iyo, Mutsuo Harano, Tokutaro Komiyama, Mitsuhiko Yamada, Ichiro Sora, Hiroshi Ujike, Nakao Iwata, Toshiya Inada, Norio Ozaki

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Methamphetamine (MAP) is one of the most frequently used illegal substances in Japan, and family and twin studies have suggested that genetic factors contribute to psychostimulant dependence, including MAP dependence. Organic cation transporter 3 (OCT3) has been reported to be involved in the disposition of MAP as well as MAP-induced behavioral changes in animals. Moreover, SLC22A3 (which encodes OCT3) is a candidate gene for MAP dependence because it is located within a chromosomal region associated with substance dependence. Methods: Using 96 healthy control subjects, linkage disequilibrium (LD) within the SLC22A3 was investigated, and 5 single-nucleotide polymorphisms (SNPs) were selected as haplotype tag SNPs to search for an association with MAP dependence. Single-marker analyses and haplotype analyses of these SNPs were performed in 213 subjects with MAP dependence and 443 healthy controls. Results: SLC22A3 polymorphisms were not significantly associated with MAP dependence in any of the single-marker and haplotype analyses. When subjects with MAP dependence were divided into polysubstance and single-MAP users, genotype and allele frequency of SNP2 (p=0.024, p=0.011, respectively), allele frequency of SNP3 (p=0.037), and haplotypic frequencies for these 2 SNPs (p=0.0438) differed significantly between groups. Conclusions: These results suggest that polymorphisms of SLC22A3 are related to the development of polysubstance use in Japanese patients with MAP dependence.

Original languageEnglish
Pages (from-to)1644-1649
Number of pages6
JournalAlcoholism: Clinical and Experimental Research
Volume30
Issue number10
DOIs
Publication statusPublished - 01-10-2006

Fingerprint

Methamphetamine
Polymorphism
Genes
Single Nucleotide Polymorphism
Nucleotides
Haplotypes
Gene Frequency
Cations
Twin Studies
Linkage Disequilibrium
Substance-Related Disorders
Healthy Volunteers
Japan
Animals
Genotype

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Toxicology
  • Psychiatry and Mental health

Cite this

Aoyama, N., Takahashi, N., Kitaichi, K., Ishihara, R., Saito, S., Maeno, N., ... Ozaki, N. (2006). Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcoholism: Clinical and Experimental Research, 30(10), 1644-1649. https://doi.org/10.1111/j.1530-0277.2006.00215.x
Aoyama, Nagisa ; Takahashi, Nagahide ; Kitaichi, Kiyoyuki ; Ishihara, Ryoko ; Saito, Shinichi ; Maeno, Nobuhisa ; Ji, Xiaofei ; Takagi, Kenji ; Sekine, Yoshimoto ; Iyo, Masaomi ; Harano, Mutsuo ; Komiyama, Tokutaro ; Yamada, Mitsuhiko ; Sora, Ichiro ; Ujike, Hiroshi ; Iwata, Nakao ; Inada, Toshiya ; Ozaki, Norio. / Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. In: Alcoholism: Clinical and Experimental Research. 2006 ; Vol. 30, No. 10. pp. 1644-1649.
@article{c77fb49e5fa54512a19806e1929333f6,
title = "Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder",
abstract = "Background: Methamphetamine (MAP) is one of the most frequently used illegal substances in Japan, and family and twin studies have suggested that genetic factors contribute to psychostimulant dependence, including MAP dependence. Organic cation transporter 3 (OCT3) has been reported to be involved in the disposition of MAP as well as MAP-induced behavioral changes in animals. Moreover, SLC22A3 (which encodes OCT3) is a candidate gene for MAP dependence because it is located within a chromosomal region associated with substance dependence. Methods: Using 96 healthy control subjects, linkage disequilibrium (LD) within the SLC22A3 was investigated, and 5 single-nucleotide polymorphisms (SNPs) were selected as haplotype tag SNPs to search for an association with MAP dependence. Single-marker analyses and haplotype analyses of these SNPs were performed in 213 subjects with MAP dependence and 443 healthy controls. Results: SLC22A3 polymorphisms were not significantly associated with MAP dependence in any of the single-marker and haplotype analyses. When subjects with MAP dependence were divided into polysubstance and single-MAP users, genotype and allele frequency of SNP2 (p=0.024, p=0.011, respectively), allele frequency of SNP3 (p=0.037), and haplotypic frequencies for these 2 SNPs (p=0.0438) differed significantly between groups. Conclusions: These results suggest that polymorphisms of SLC22A3 are related to the development of polysubstance use in Japanese patients with MAP dependence.",
author = "Nagisa Aoyama and Nagahide Takahashi and Kiyoyuki Kitaichi and Ryoko Ishihara and Shinichi Saito and Nobuhisa Maeno and Xiaofei Ji and Kenji Takagi and Yoshimoto Sekine and Masaomi Iyo and Mutsuo Harano and Tokutaro Komiyama and Mitsuhiko Yamada and Ichiro Sora and Hiroshi Ujike and Nakao Iwata and Toshiya Inada and Norio Ozaki",
year = "2006",
month = "10",
day = "1",
doi = "10.1111/j.1530-0277.2006.00215.x",
language = "English",
volume = "30",
pages = "1644--1649",
journal = "Alcoholism: Clinical and Experimental Research",
issn = "0145-6008",
publisher = "Wiley-Blackwell",
number = "10",

}

Aoyama, N, Takahashi, N, Kitaichi, K, Ishihara, R, Saito, S, Maeno, N, Ji, X, Takagi, K, Sekine, Y, Iyo, M, Harano, M, Komiyama, T, Yamada, M, Sora, I, Ujike, H, Iwata, N, Inada, T & Ozaki, N 2006, 'Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder', Alcoholism: Clinical and Experimental Research, vol. 30, no. 10, pp. 1644-1649. https://doi.org/10.1111/j.1530-0277.2006.00215.x

Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. / Aoyama, Nagisa; Takahashi, Nagahide; Kitaichi, Kiyoyuki; Ishihara, Ryoko; Saito, Shinichi; Maeno, Nobuhisa; Ji, Xiaofei; Takagi, Kenji; Sekine, Yoshimoto; Iyo, Masaomi; Harano, Mutsuo; Komiyama, Tokutaro; Yamada, Mitsuhiko; Sora, Ichiro; Ujike, Hiroshi; Iwata, Nakao; Inada, Toshiya; Ozaki, Norio.

In: Alcoholism: Clinical and Experimental Research, Vol. 30, No. 10, 01.10.2006, p. 1644-1649.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder

AU - Aoyama, Nagisa

AU - Takahashi, Nagahide

AU - Kitaichi, Kiyoyuki

AU - Ishihara, Ryoko

AU - Saito, Shinichi

AU - Maeno, Nobuhisa

AU - Ji, Xiaofei

AU - Takagi, Kenji

AU - Sekine, Yoshimoto

AU - Iyo, Masaomi

AU - Harano, Mutsuo

AU - Komiyama, Tokutaro

AU - Yamada, Mitsuhiko

AU - Sora, Ichiro

AU - Ujike, Hiroshi

AU - Iwata, Nakao

AU - Inada, Toshiya

AU - Ozaki, Norio

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Background: Methamphetamine (MAP) is one of the most frequently used illegal substances in Japan, and family and twin studies have suggested that genetic factors contribute to psychostimulant dependence, including MAP dependence. Organic cation transporter 3 (OCT3) has been reported to be involved in the disposition of MAP as well as MAP-induced behavioral changes in animals. Moreover, SLC22A3 (which encodes OCT3) is a candidate gene for MAP dependence because it is located within a chromosomal region associated with substance dependence. Methods: Using 96 healthy control subjects, linkage disequilibrium (LD) within the SLC22A3 was investigated, and 5 single-nucleotide polymorphisms (SNPs) were selected as haplotype tag SNPs to search for an association with MAP dependence. Single-marker analyses and haplotype analyses of these SNPs were performed in 213 subjects with MAP dependence and 443 healthy controls. Results: SLC22A3 polymorphisms were not significantly associated with MAP dependence in any of the single-marker and haplotype analyses. When subjects with MAP dependence were divided into polysubstance and single-MAP users, genotype and allele frequency of SNP2 (p=0.024, p=0.011, respectively), allele frequency of SNP3 (p=0.037), and haplotypic frequencies for these 2 SNPs (p=0.0438) differed significantly between groups. Conclusions: These results suggest that polymorphisms of SLC22A3 are related to the development of polysubstance use in Japanese patients with MAP dependence.

AB - Background: Methamphetamine (MAP) is one of the most frequently used illegal substances in Japan, and family and twin studies have suggested that genetic factors contribute to psychostimulant dependence, including MAP dependence. Organic cation transporter 3 (OCT3) has been reported to be involved in the disposition of MAP as well as MAP-induced behavioral changes in animals. Moreover, SLC22A3 (which encodes OCT3) is a candidate gene for MAP dependence because it is located within a chromosomal region associated with substance dependence. Methods: Using 96 healthy control subjects, linkage disequilibrium (LD) within the SLC22A3 was investigated, and 5 single-nucleotide polymorphisms (SNPs) were selected as haplotype tag SNPs to search for an association with MAP dependence. Single-marker analyses and haplotype analyses of these SNPs were performed in 213 subjects with MAP dependence and 443 healthy controls. Results: SLC22A3 polymorphisms were not significantly associated with MAP dependence in any of the single-marker and haplotype analyses. When subjects with MAP dependence were divided into polysubstance and single-MAP users, genotype and allele frequency of SNP2 (p=0.024, p=0.011, respectively), allele frequency of SNP3 (p=0.037), and haplotypic frequencies for these 2 SNPs (p=0.0438) differed significantly between groups. Conclusions: These results suggest that polymorphisms of SLC22A3 are related to the development of polysubstance use in Japanese patients with MAP dependence.

UR - http://www.scopus.com/inward/record.url?scp=33749044448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749044448&partnerID=8YFLogxK

U2 - 10.1111/j.1530-0277.2006.00215.x

DO - 10.1111/j.1530-0277.2006.00215.x

M3 - Article

VL - 30

SP - 1644

EP - 1649

JO - Alcoholism: Clinical and Experimental Research

JF - Alcoholism: Clinical and Experimental Research

SN - 0145-6008

IS - 10

ER -